Segall Bryant & Hamill LLC Sells 1,407 Shares of Glaukos Co. (NYSE:GKOS)

Segall Bryant & Hamill LLC lessened its holdings in Glaukos Co. (NYSE:GKOS) by 1.3% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 104,549 shares of the medical instruments supplier’s stock after selling 1,407 shares during the period. Segall Bryant & Hamill LLC’s holdings in Glaukos were worth $15,676,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. IFP Advisors Inc bought a new position in Glaukos in the fourth quarter worth approximately $43,000. Asset Planning Inc bought a new position in Glaukos in the 4th quarter worth $90,000. Picton Mahoney Asset Management purchased a new position in Glaukos during the fourth quarter valued at $125,000. Harvest Fund Management Co. Ltd grew its holdings in Glaukos by 2,263.2% during the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 860 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new stake in Glaukos in the fourth quarter worth about $153,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Truist Financial lifted their price objective on Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Mizuho upgraded shares of Glaukos from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $140.00 to $200.00 in a research report on Wednesday, February 19th. Morgan Stanley downgraded shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective on the stock. in a research report on Monday, December 2nd. Needham & Company LLC upped their target price on shares of Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Finally, Citigroup upgraded Glaukos from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $132.00 to $162.00 in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $163.25.

Insider Buying and Selling

In other news, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.40% of the stock is currently owned by company insiders.

Glaukos Stock Down 0.8 %

NYSE GKOS opened at $106.72 on Wednesday. The stock has a 50 day moving average price of $133.61 and a 200-day moving average price of $136.29. Glaukos Co. has a one year low of $87.59 and a one year high of $163.71. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The company has a market capitalization of $6.04 billion, a P/E ratio of -37.18 and a beta of 0.99.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The business had revenue of $105.50 million during the quarter, compared to analysts’ expectations of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. As a group, equities analysts predict that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.